ClinConnect ClinConnect Logo
Search / Trial NCT06460038

Tenapanor in Synucleinopathy-Related Constipation

Launched by CEDAR VALLEY DIGESTIVE HEALTH CENTER · Jun 11, 2024

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Tenapanor Synucleinopathy Parkinson's Disease Constipation

ClinConnect Summary

This clinical trial is studying a medication called tenapanor to see if it can help people with Parkinson's Disease who are experiencing constipation. Constipation is a common issue for those with this condition, and the trial aims to find an effective treatment. The researchers are currently looking for participants aged 50 to 89 years who have been diagnosed with Parkinson's Disease and have specific bowel movement issues, such as having fewer than six bowel movements a week.

If you or someone you know is interested in participating, it’s important to know that certain conditions must be met. For example, potential participants should not have other serious gastrointestinal problems or significant liver or kidney issues. During the trial, participants will likely be monitored closely to assess how well tenapanor works for relieving constipation. Overall, this study could lead to better treatment options for those facing constipation due to Parkinson's Disease.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • 1. Age 50-89 years.
  • 2. Diagnosis of PD within Hoehn and Yahr stages 1-3, confirmed by a neurologist per International Parkinson and Movement Disorder Society criteria.
  • 3. Average weekly stool frequency of ≤5 spontaneous bowel movements (SBMs) and ≤2 complete spontaneous bowel movements (CSBMs) over the past 6 months. These criteria will be verified during a 2-week screening period.
  • 4. Stool consistency ≤3 on the Bristol Stool Form Scale (BSFS). This criterion will be verified during a 2-week screening period.
  • 5. Agreement to use contraception, if applicable.
  • Exclusion Criteria
  • 1. Functional diarrhea or IBS-D/M based on Rome IV Criteria.
  • 2. Symptomatic structural GI abnormalities or inflammatory bowel disease.
  • 3. Significant hepatic (ALT or AST ≥ 2.5x the upper limit of normal) or renal (serum creatinine \>2mg/dl) dysfunction.
  • 4. Pregnancy or lactation.
  • 5. Diagnosis of primary dyssynergic defecation by anorectal manometry.

About Cedar Valley Digestive Health Center

Cedar Valley Digestive Health Center is a leading clinical trial sponsor dedicated to advancing gastrointestinal health through innovative research and clinical studies. With a team of experienced gastroenterologists and clinical researchers, the center focuses on developing and evaluating new treatments and therapies for various digestive disorders. Committed to patient-centered care, Cedar Valley Digestive Health Center emphasizes the importance of ethical standards and rigorous scientific methodology in their trials, aiming to improve treatment outcomes and enhance the quality of life for patients suffering from digestive health issues.

Locations

Waterloo, Iowa, United States

Patients applied

0 patients applied

Trial Officials

Richard A. Manfready, MD, AM, FACP

Principal Investigator

Cedar Valley Digestive Health Center

Ravindra Mallavarapu, MD

Study Chair

Cedar Valley Digestive Health Center

Harichandana Punukula, PharmD, MS

Study Director

Cedar Valley Digestive Health Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported